Evidence map›Paper›PMID 27498622›Full record

ArticleVaccine2016

Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4(+) T cells but no increase in avidity for Ag85A.

Hannah J Metcalfe, Sabine Steinbach, Gareth J Jones, Tim Connelley, W Ivan Morrison, Martin Vordermeier, Bernardo Villarreal-Ramos

Abstract read
In one paragraph

Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Recent Characterization of Key Proteins to Combat Tuberculosis.Advances in experimental medicine and biology · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Ag85A-specific CD4Vaccine · 2018
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hannah J MetcalfeTB Immunology and Vaccinology Team, Department of Bacteriology, Animal and Plant Health Agency, Weybridge, Surrey KT15 3NB, UK; Immunity Division, The Roslin Institute, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian EH25 9RG, UK.
Sabine SteinbachTB Immunology and Vaccinology Team, Department of Bacteriology, Animal and Plant Health Agency, Weybridge, Surrey KT15 3NB, UK.
Gareth J JonesTB Immunology and Vaccinology Team, Department of Bacteriology, Animal and Plant Health Agency, Weybridge, Surrey KT15 3NB, UK.
Tim ConnelleyImmunity Division, The Roslin Institute, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian EH25 9RG, UK.
W Ivan MorrisonImmunity Division, The Roslin Institute, Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian EH25 9RG, UK.
Martin VordermeierTB Immunology and Vaccinology Team, Department of Bacteriology, Animal and Plant Health Agency, Weybridge, Surrey KT15 3NB, UK.
Bernardo Villarreal-RamosTB Immunology and Vaccinology Team, Department of Bacteriology, Animal and Plant Health Agency, Weybridge, Surrey KT15 3NB, UK. Electronic address: Bernardo.Villarreal-Ramos@apha.gsi.gov.uk.

Funding

Biotechnology and Biological Sciences Research Council BBS/E/D/05201236
6 · The paper itself

Abstract

There is a need to improve the efficacy of Bacille Calmette-Guérin (BCG) vaccination against tuberculosis in humans and cattle. Previously, we found boosting BCG-primed cows with recombinant human type 5 adenovirus expressing antigen 85A (Ad5-85A) increased protection against Mycobacterium bovis infection compared to BCG vaccination alone. The aim of this study was to decipher aspects of the immune response associated with this enhanced protection. We compared BCG-primed Ad5-85A-boosted cattle with BCG-vaccinated cattle. Polyclonal CD4(+) T cell libraries were generated from pre-boost and post-boost peripheral blood mononuclear cells - using a method adapted from Geiger et al. (2009) - and screened for antigen 85A (Ag85A) specificity. Ag85A-specific CD4(+) T cell lines were analysed for their avidity for Ag85A and their Ag85A epitope specificity was defined. Boosting BCG with Ad5-85A increased the frequencies of post-boost Ag85A-specific CD4(+) T cells which correlated with protection (reduced pathology). Boosting Ag85A-specific CD4(+) T cell responses did not increase their avidity. The epitope specificity was variable between animals and we found no clear evidence for a post-boost epitope spreading. In conclusion, the protection associated with boosting BCG with Ad5-85A is linked with increased frequencies of Ag85A-specific CD4(+) T cells without increasing avidity or widening of the Ag85A-specific CD4(+) T cell repertoire.

Indexed as

AcyltransferasesAnimalsAntigens, BacterialBCG VaccineCattleCD4-Positive T-LymphocytesEpitopes, T-LymphocyteFemaleLeukocytes, MononuclearMycobacterium bovisTuberculosisAcyltransferasesantigen 85A, Mycobacterium tuberculosisAntigens, BacterialBCG VaccineEpitopes, T-LymphocyteBovine tuberculosisImmunological protectionVaccination

Identifiers

PMID27498622
PMCPMC5009893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.